Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(20)32469-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanistic insights into ruxolitinib cream for mild hidradenitis suppurativa.
Br J Dermatol
January 2025
Division of Infection & Immunity, Cardiff University, Cardiff, UK.
Article Synopsis
- Ruxolitinib cream, shown to be safe and effective in a phase 3 study, has demonstrated its anti-inflammatory and itch-relieving properties in children aged 2-11 with mild to moderate atopic dermatitis (AD).
- The study focused on assessing safety, tolerability, pharmacokinetics, and quality of life while using the cream at maximum levels over longer periods, with 29 children participating and applying the cream twice daily for 4 weeks, followed by individualized usage.
- Results indicated that 31% of participants experienced treatment-related adverse events, but no severe health issues arose, and significant improvements in skin condition and quality of life were sustained for up to 52 weeks.
Pilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa.
Br J Dermatol
December 2024
The Pennsylvania State University College of Medicine, Department of Dermatology, Hershey, PA, USA.
Background: Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no FDA approved therapies for early stage HS. Topical JAnus Kinase inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signaling in HS lesions and the recent success of systemic JAKi for moderate to severe HS.
Objectives: This is a pilot, single-site, open-label, prospective 24-week clinical trial with topical ruxolitinib (NCT04414514).
Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024.
Expert Opin Drug Saf
December 2024
Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.
Background: Ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, is a widely used treatment for various dermatological diseases. This study employs the FDA Adverse Event Reporting System (FAERS) database to examine adverse events (AEs) associated with ruxolitinib cream.
Methods: This study employed disproportionate analysis methods, including reported odds ratio and proportional reporting ratio, to collate AEs reported from the fourth quarter of 2021 to the first quarter of 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!